The life expectancy of patients with hepatitis B is not adversely affected by antiviral therapy, only in a favorable way. Because antiviral treatment for hepatitis B blocks the damage caused by the hepatitis B virus to the liver, the patient’s life expectancy is not significantly affected if the liver is maintained in a relatively good condition. However, if the hepatitis B patient’s liver is in a state of cirrhosis and has entered the decompensated phase with various complications when antiviral treatment is started, the life expectancy will be affected to a certain extent and will be shorter if the anti-hepatitis B virus medication is not taken. However, after good antiviral treatment, cirrhosis will block the hepatitis B virus, and if the various symptoms of cirrhotic patients can be maintained by other methods, the patient’s life expectancy can be somewhat extended, but it is also slightly shortened compared to normal people. If the general shape of the liver is basically normal when antiviral treatment is started, the patient’s life expectancy will be basically the same as that of a normal person.